Progyny (NASDAQ:PGNY) Director Kevin Gordon Sells 5,500 Shares

Progyny, Inc. (NASDAQ:PGNY) Director Kevin Gordon sold 5,500 shares of Progyny stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $24.99, for a total transaction of $137,445.00. Following the transaction, the director owned 9,318 shares of the company’s stock, valued at approximately $232,856.82. The trade was a 37.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Progyny Price Performance

PGNY traded down $0.12 during midday trading on Friday, reaching $25.57. 1,307,342 shares of the company’s stock were exchanged, compared to its average volume of 1,555,858. The stock has a market capitalization of $2.00 billion, a PE ratio of 33.21, a P/E/G ratio of 1.35 and a beta of 0.91. The business’s 50-day moving average price is $19.68 and its 200 day moving average price is $22.22. Progyny, Inc. has a 1-year low of $16.10 and a 1-year high of $28.75.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, May 7th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.24. The company had revenue of $328.50 million during the quarter, compared to analysts’ expectations of $326.47 million. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The firm’s quarterly revenue was down 26.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, analysts expect that Progyny, Inc. will post 1.12 EPS for the current fiscal year.

Progyny declared that its Board of Directors has initiated a share repurchase program on Tuesday, May 26th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the company to buy up to 10.3% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.

Institutional Investors Weigh In On Progyny

A number of institutional investors have recently bought and sold shares of PGNY. Wellington Management Group LLP grew its holdings in Progyny by 260.9% in the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after purchasing an additional 1,621,688 shares during the period. Fort Washington Investment Advisors Inc. OH grew its holdings in Progyny by 46.9% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock valued at $45,734,000 after purchasing an additional 859,289 shares during the period. Loomis Sayles & Co. L P purchased a new stake in Progyny during the fourth quarter worth approximately $19,917,000. Barclays PLC grew its stake in Progyny by 79.2% during the third quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock worth $33,904,000 after buying an additional 696,447 shares during the period. Finally, Ameriprise Financial Inc. grew its stake in Progyny by 37.6% during the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after buying an additional 545,431 shares during the period. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on PGNY. Zacks Research raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. KeyCorp cut their price objective on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. Jefferies Financial Group reissued a “buy” rating and issued a $30.00 price objective on shares of Progyny in a research report on Friday, March 6th. Canaccord Genuity Group raised shares of Progyny from a “hold” rating to a “buy” rating and boosted their price objective for the company from $19.00 to $30.00 in a research report on Tuesday, May 19th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Progyny in a research report on Friday, March 27th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Progyny has a consensus rating of “Moderate Buy” and an average price target of $29.55.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.